LivaNova plc (LIVN)
79.48
-0.22 (0.28%)
Upcoming Events
Latest Headlines
LIVANOVA reports 84.5% response rate with PolySync in sleep apnea study
June 16, 2026 10:58 AM - StreetInsider
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
June 16, 2026 10:58 AM - BizWire
Form 144 LivaNova PLC Filed by: Bianchi Francesco
June 15, 2026 4:57 PM - SEC Filing
LivaNova appoints Jette Nygaard-Andersen to board of directors
June 11, 2026 1:44 PM - StreetInsider
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
June 11, 2026 1:44 PM - BizWire
Form 3 LivaNova PLC For: Jun 10 Filed by: Nygaard-Andersen Jette
June 11, 2026 9:22 AM - SEC Filing
Form 8-K LivaNova PLC For: Jun 10
June 11, 2026 9:08 AM - SEC Filing
LivaNova names Anne Liddy as chief legal officer
June 5, 2026 9:00 AM - StreetInsider
LivaNova Appoints Anne Liddy as Chief Legal Officer
June 5, 2026 9:00 AM - BizWire
Form SD LivaNova PLC
May 29, 2026 4:13 PM - SEC Filing
Form 4 LivaNova PLC For: May 26 Filed by: Bianchi Francesco
May 27, 2026 4:51 PM - SEC Filing
Form 144 LivaNova PLC Filed by: Bianchi Francesco
May 26, 2026 4:42 PM - SEC Filing
LivaNova names Stefano Folli to head cardiopulmonary unit
May 21, 2026 9:15 AM - StreetInsider
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
May 21, 2026 9:15 AM - BizWire
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
May 19, 2026 8:00 AM - BizWire
Livanova (LIVN) PT Lowered to $76 at Baird
May 7, 2026 7:10 AM - StreetInsider
Livanova (LIVN) PT Raised to $90 at Mizuho
May 7, 2026 6:50 AM - StreetInsider
Livanova (LIVN) PT Raised to $76 at Barclays
May 7, 2026 4:01 AM - StreetInsider
Form IRANNOTICE LivaNova PLC
May 6, 2026 1:04 PM - SEC Filing
Form 10-Q LivaNova PLC For: Mar 31
May 6, 2026 1:02 PM - SEC Filing
Form 8-K LivaNova PLC For: May 06
May 6, 2026 6:08 AM - SEC Filing
LivaNova plc (LIVN) Tops Q1 EPS by 8c, Beats on Revenue; Offers FY26 EPS Guidance
May 6, 2026 6:05 AM - StreetInsider
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
May 6, 2026 6:00 AM - BizWire
Form SCHEDULE 13G/A LivaNova PLC Filed by: INTEGRATED CORE STRATEGIES (US) LLC
April 30, 2026 7:45 PM - SEC Filing
Form ARS LivaNova PLC For: Dec 31
April 29, 2026 8:34 AM - SEC Filing
Form DEFA14A LivaNova PLC
April 29, 2026 8:32 AM - SEC Filing
Form DEF 14A LivaNova PLC For: Jun 10
April 29, 2026 8:30 AM - SEC Filing
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea
April 20, 2026 5:05 PM - BizWire
Livanova (LIVN) PT Lowered to $78 at Baird
April 15, 2026 6:27 AM - StreetInsider
Form 4 LivaNova PLC For: Mar 30 Filed by: Tezel Ahmet
April 1, 2026 5:21 PM - SEC Filing
Form 4 LivaNova PLC For: Mar 30 Filed by: Poletti Franco
April 1, 2026 5:20 PM - SEC Filing
Form 4 LivaNova PLC For: Mar 30 Filed by: Makatsaria Vladimir
April 1, 2026 5:20 PM - SEC Filing
Form 4 LivaNova PLC For: Mar 30 Filed by: Shvartsburg Alex
April 1, 2026 5:20 PM - SEC Filing
Form 4 LivaNova PLC For: Mar 30 Filed by: Bolton Stephanie
April 1, 2026 5:20 PM - SEC Filing
Form 4 LivaNova PLC For: Mar 30 Filed by: Kozmina Natalia
April 1, 2026 5:20 PM - SEC Filing
MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value
March 27, 2026 10:15 AM - PR NewsWire
LivaNova to Announce First-Quarter 2026 Results
March 25, 2026 9:00 AM - BizWire
LivaNova gets FDA approval for sleep apnea device without collapse warning
March 19, 2026 8:32 AM - StreetInsider
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
March 19, 2026 8:30 AM - BizWire
Full Article List
